Sapient Capital’s Biogen BIIB Stock Holding History

Sapient Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,143	Closed	-$210K	–	407
2026 Q1	$210K	Buy	+1,143	New	+$211K	﹤0.01%	421

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sapient Capital's BIIB Position: Q2 2026 in Review

Sapient Capital sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,143 shares — an estimated $210K sold.

Sapient Capital first reported a position in BIIB in Q1 2026 and held it in 1 quarter. The position peaked at $210K in Q1 2026. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Sapient Capital reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Sapient Capital sold 1,143 Biogen shares in Q2 2026, an estimated $210K.
Sapient Capital first reported a position in Biogen in Q1 2026 and held it in 1 quarter.
Sapient Capital's Biogen position peaked at $210K in Q1 2026.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.